spacer
home > ebr > Spring 2005
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2005
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Tayton-Martin reviews the articles in this issue  
download pdf
BioBusiness, Finance & Communication
Dirk Kersten, Investment Manager at Gilde Investment Management, summarises the trends in financing that emerged in 2004 and offers a forecast on the Funding Outlook for 2005: Public or Private?  
download pdf
A guide to negotiating the complex domain of Intellectual Property Issues in Bio-Industry Corporate Transactions, is presented by George Godar, Partner and Selina Taylor, Solicitor at DLA Piper Rudnick Gray Cary LLP  
download pdf
Helen Tayton-Martin, Technology Consultant at London Technology Network and Advisory Editor of EBR, interviews CEO Christopher Pearce and uncovers the life story of a biotech company, in Entrepreneurship in Action - In Conversation with Proteome Sciences  
download pdf
Gugs Lushai, Manager of BioApproaches SW, and Julian Beer, Senior Lecturer and Director (Research), Social Research and Regeneration Unit, Faculty of Social Science and Business at the University of Plymouth, consider the training and employment issues to be resolved for optimisation of industry performance, in Biotechnology Workforce Development for Sector Promotion  
download pdf
Science and Innovation
In Vioxx: Lifting the Veil on the Dark Side of the Pharmaceutical Industry, Catherine Pichereau, Senior Consultant at Bionest Partners, considers the new concerns, objectives and possibilities arising from the withdrawal of Merck's COX-2 inhibitor  
download pdf
Superbugs: Apocalypse Now or The Day After Tomorrow? Malcolm Page, Head of Biology and Jutta Heim, Chief Science Officer at Basilea, discuss the self-negating quality of antibiotics, cautioning us on the need to keep pace with emerging resistant strains 46 Dr A Knowles, Raman Division Manager and Dr S FitzGerald, Raman and XRF Micro-Analysis Specialist at Horiba JobinYvon, investigate Biopharma Imaging and Analysis - Advancing Towards a More Detailed Picture of Chemistry  
download pdf
Thirty years after the publication of a method to develop monoclonal antibodies, their evolving potential is evaluated, in The New Wave in mAbs Therapeutics - Putting High Expectations in Perspective, by Dr John Wijdenes, General Director of Diaclone SAS  
download pdf
BioDiscovery
Robert Verhagen, Senior Director, Biomarker Development at MDS Pharma Services, discusses new methods of streamlining drug development, in Making Biomarkers Pay  
download pdf
In Multiplexed Microarray - New Approaches for Biomarker Discovery, Dr Jeremy Clarke, Global Product Manager at Genomic Solutions Ltd, welcomes the emergence of techniques to optimise drug discovery and personalise disease management  
download pdf
Pavel Hradecky, Pierre Stanislawski, Simon de Bernard and Laurent Buffat at IT.Omics, inform us of the latest developments in Biological Pathways in Pharma Discovery Strategies: From Information Source to Innovative Insight, stressing the necessity of an integrative approach to data interpretation  
download pdf
Indispensable in the field of molecular biology, the full potential of siRNA is yet to unfold, asserts Dr Klaus Giese, Chief Scientific Officer, Vice President of Research and Member of the Management Board at Atugen, in Poised to Change the Health Care Landscape - siRNA Therapeutics  
download pdf
BioDevelopment
Translational Medicine: Friend or Foe to Drug Discovery? Professor Anthony C Woodman, Professor of Translational Medicine at Cranfield University, expounds the benefits of improved enhanced communication and symbiosis within the health care industry  
download pdf
Intergration and collaboration are key to the success of drug discovery efforts, argues Dr Jon M Wigginton, Head of the Investigational Biologics Section, Pediatric Oncology Branch at the Center for Cancer Research, Maryland, US, in Translational Research and Oncology Drug Development: Opportunities and Obstacles  
download pdf
Victoria Doel, Clinical Integration Manager, Marie MacDonald Director of Strategic Product Development and Robyn Wood Operations Medication Management Specialist at ClinPhone, discuss the potential of voice and web response technologies to enhance drug reconciliation, in Bringing Information Technology to Drug Returns  
download pdf
BioManufacturing
In Advances in Immune Monitoring - New and Improved Tools for the Successful Development of Biologic Therapies and Vaccines, Dr Peter Trinder, Co-Founder and CEO of Thymed GmbH, puts forward new methodologies improving drug development  
download pdf
In The National Biomanufacturing Centre - Building on Bioprocessing Expertise, Dr Derek Ellison, Business Development Director of Eden Biodesign, underlines the importance of biotech to national economies and anticipates the addition of a valuable asset to the UK industry  
download pdf
Gerrit Hagens, President and COO of ExcellGene, describes the conceptual basis of the Production of Therapeutic Proteins from Mammalian Cells and recent developments in their manufacture  
download pdf
Traditional and single-use systems are compared in terms of cost, project timelines, flexibility and validation requirements in Biotech Process Optimisation Through Implementation Of Disposable Technologies - An Overview, by Miriam Monge, Marketing Director at Stedim SA  
download pdf
Dr Jose Arnau, Business Development Manager at Unizyme Laboratories A/S, outlines the value of His-Tag - A Powerful Tool for the Production of Recombinant Proteins in the Pharmaceutical Industry, providing an overview of production processes, choices and strategies  
download pdf
bullet
Regional Focus: Göteborg
In Göteborg - The Biotechnology Port of Call, Olivia Lindau-Jonsson, Project Co-ordinator at Business Region Göteborg, evaluates the challenges, successes and future ambitions of biotech in the Swedish city  
download pdf
bullet
Preview
Dr Patricia Lobo, Editor of PMPS and Associate Director of Technomark, reports on the official recognition of merit in an innovative company, in Bluepharma Awarded by European Commission  
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement